BCG Vaccination ReactionbcgscarsNCT03548233
BCG Vaccination Scar Formation in Children Under Five Years :Factors Affecting Its Formation and Subsequent Adverse Effects .
A study testing bcg vaccine in people with BCG Vaccination Reaction, run by Assiut University.
Trial summary
Study of BCG Vaccination scars of under five years old children . Estimation of the frequency of children without BCG scar after BCG vaccine . Evaluation of factors which may affect scar formation . Tuberculin skin test response in children without BCG scar . Read more about this study
- Who is it for?
- Ages 6 months to 5 yearsHealthy volunteers can take part
- Conditions the study is for
- BCG Vaccination Reaction
- What is being tested?
- bcg vaccine
- Type of treatment
- Vaccines
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- 1 May 2021to 1 Dec 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 months to 5 years
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Children between 6 and 60 months of age.
Who cannot join
- • Infants with skin lesion on the left forearm.
- Infant treated with steroids or intravenous immune globulins.
- Infants with immunodeficiency and malnutrition.
- Severe sepsis.
Trial locations and contacts
No sites are listed yet.
About this study
Study of BCG Vaccination scars of under five years old children . Estimation of the frequency of children without BCG scar after BCG vaccine . Evaluation of factors which may affect scar formation . Tuberculin skin test response in children without BCG scar . Frequency of vaccine adverse effects as injection-site abscess, lymphadenitis, severe local reaction, and disseminated BCG infection.
Read the detailed description
Tuberculosis (TB) is an ancient disease, with evidence of skeletal TB found in mummies in both the Old and New World. The causative agent is Mycobacterium tuberculosis, a fastidious, aerobic, acid-fast bacillus Tuberculosis (TB) remains a major global health problem. It ranks as the second leading cause of death from an infectious disease worldwide, after the human immunodeficiency virus (HIV). The latest estimates by the World Health Organization (WHO) reported that there were 9 million new cases in 2011 and 1.4 million TB deaths . Moreover, it is one of the top 10 causes of global mortality and affects low-income countries in particular. About half a million children (0-14 years old) are ill with TB, and 64,000 children died from the disease in 2011 . In Egypt, TB is considered the third most important public health problem after schistosomiasis and hepatitis C .
TB in children is often missed or overlooked due to non-specific symptoms and difficulties in diagnosis. This has made it difficult to assess the actual magnitude of the childhood TB epidemic, which may be higher than currently estimated.
There is an urgent need for public attention, prioritisation, commitment and funding for this disease that today should never take the life of a child.
Bacillus Calmette-Guérin (BCG) vaccine : a live attenuated vaccine that has been in use since 1921, is the most widely used vaccine worldwide . BCG is efficacious against the most severe forms of tuberculosis (TB) such as tuberculosis meningitis (73% protection) and miliary TB (77% protection) in children younger than 5 years .
It is one of the mandatory vaccines recommended by the ministry of health(MOH) of Egypt.
BCG vaccination became compulsory in all governorates of Egypt since 1974 . the recommended schedule of BCG is eight weeks postnatal. The usual response to administer BCG vaccine is the development of erythema or a papule at around 2 weeks, followed by an ulcer and healing with a scar at 6 weeks at the site of the injection.
Although the size of reaction after vaccination is not generally thought to influence the degree of protection offered by BCG, the presence of the BCG scar has been used as a criterion to assess the uptake of vaccination .
However, the sensitivity of BCG scar as an index of vaccination status is still the subject of controversy. Failure to form scar may be related to factors such as lack of maturation of the immune system, faulty technique or unipotent vaccine.
Adverse effects of Bcg vaccine: were classified, according to World Health Organization definitions , as injection-site abscess, lymphadenitis, severe local reaction, and disseminated BCG infection.
Tuberculin skin test response:
The reaction is read by measuring the diameter of induration (palpable raised, hardened area) across the forearm (perpendicular to the long axis) in millimeters. If there is no induration, the result should be recorded as "0 mm". Erythema (redness) should not be measured.
- 5 mm or more is positive in
- An HIV-positive person
- Persons with recent contacts with a TB patient
- Persons with nodular or fibrotic changes on chest X-ray consistent with old healed TB
- Patients with organ transplants, and other immunosuppressed patients
- 10 mm or more is positive in
- Recent arrivals (less than five years) from high-prevalence countries
- Injection drug users
- Residents and employees of high-risk congregate settings (e.g., prisons, nursing homes, hospitals, homeless shelters, etc.)
- Mycobacteriology lab personnel
- Persons with clinical conditions that place them at high risk (e.g., diabetes, prolonged corticosteroid therapy, leukemia, end-stage renal disease, chronic malabsorption syndromes, low body weight, etc.)
- Children less than four years of age, or children and adolescents exposed to adults in high-risk categories
- 15 mm or more is positive in
- Persons with no known risk factors for TB. the study aims to• Estimate the frequency of children without BCG scar after bcg vaccination.
- Evaluate factors which may affect scar formation.
- Tuberculin skin test response in children without BCG scars if indicated.
- Frequency of vaccine adverse effects
Exclusion criteria:
- Infants with skin lesion on the left forearm.
- Infant treated with steroids or intravenous immune globulins.
- Infants with immunodeficiency.
- Severe sepsis.
- Infants with congenital anomalies.
All cases included in the study will be subjected to
- Full clinical history including: Birth weight, nutritional status, gender, gestational age, weight at time of vaccination, mother awareness.
- Detailed clinical examination: including site of bcg scar.
- Tuberculin test in negative BCG scar children.
- Revaccination of negative BCG scar children.
- Conditions
- BCG Vaccination Reaction
- Being tested
- bcg vaccine
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
bcg vaccineBiological
live attenuated vaccine
| Study group | Role | What they receive |
|---|---|---|
| bcg vaccinated | Other | children under five year vaccinated by bcg vaccine Receives: Biological: bcg vaccine |
What is being measured
The primary outcome is the main question the study is designed to answer.
number of children without bcg scar after bcg vaccination and factors that may lead to that nummber of children with adverse effects from bcg vaccine using clinical data about children included in the study
bcg vaccination reaction and adverse effects and factors affecting scar formation
Measured: one year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jun 2018
- Study start1 May 2021 (estimated)
- Primary completion1 Dec 2021 (estimated)
- Study completion1 Dec 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for BCG Vaccination ReactionStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- bcg vaccine
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Shimaa Abd elhamid Mahran, Assiut University
- Investigators
- mohamed ghazaly, professor, Principal investigator, assiut universitypediatric hospitalmustafa embaby, assistprof, Principal investigator, assiut universitypediatric hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03548233
- Sponsor's protocol ID
- bcgvaccinationscars
- Acronym
- bcgscars
- Status last verified
- Mar 2021
- First submitted
- 11 May 2018
- Last updated
- 16 Mar 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Mar 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- BCG Vaccination Scar Formation in Children Under Five Years :Factors Affecting Its Formation and Subsequent Adverse Effects .
- ClinicalTrials.gov ID
- NCT03548233
- Acronym / sponsor ID
- bcgscars / bcgvaccinationscars
- Conditions
- BCG Vaccination Reaction
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 May 2021 (estimated)
- Primary completion
- 1 Dec 2021 (estimated)
- Study completion
- 1 Dec 2021 (estimated)
- First posted
- 7 Jun 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Study of BCG Vaccination scars of under five years old children . Estimation of the frequency of children without BCG scar after BCG vaccine . Evaluation of factors which may affect scar formation . Tuberculin skin test response in children without BCG scar . Frequency of vaccine adverse effects as injection-site abscess, lymphadenitis, severe local reaction, and disseminated BCG infection.
Detailed description
Tuberculosis (TB) is an ancient disease, with evidence of skeletal TB found in mummies in both the Old and New World. The causative agent is Mycobacterium tuberculosis, a fastidious, aerobic, acid-fast bacillus Tuberculosis (TB) remains a major global health problem. It ranks as the second leading cause of death from an infectious disease worldwide, after the human immunodeficiency virus (HIV). The latest estimates by the World Health Organization (WHO) reported that there were 9 million new cases in 2011 and 1.4 million TB deaths . Moreover, it is one of the top 10 causes of global mortality and affects low-income countries in particular. About half a million children (0-14 years old) are ill with TB, and 64,000 children died from the disease in 2011 . In Egypt, TB is considered the third most important public health problem after schistosomiasis and hepatitis C .
TB in children is often missed or overlooked due to non-specific symptoms and difficulties in diagnosis. This has made it difficult to assess the actual magnitude of the childhood TB epidemic, which may be higher than currently estimated.
There is an urgent need for public attention, prioritisation, commitment and funding for this disease that today should never take the life of a child.
Bacillus Calmette-Guérin (BCG) vaccine : a live attenuated vaccine that has been in use since 1921, is the most widely used vaccine worldwide . BCG is efficacious against the most severe forms of tuberculosis (TB) such as tuberculosis meningitis (73% protection) and miliary TB (77% protection) in children younger than 5 years .
It is one of the mandatory vaccines recommended by the ministry of health(MOH) of Egypt.
BCG vaccination became compulsory in all governorates of Egypt since 1974 . the recommended schedule of BCG is eight weeks postnatal. The usual response to administer BCG vaccine is the development of erythema or a papule at around 2 weeks, followed by an ulcer and healing with a scar at 6 weeks at the site of the injection.
Although the size of reaction after vaccination is not generally thought to influence the degree of protection offered by BCG, the presence of the BCG scar has been used as a criterion to assess the uptake of vaccination .
However, the sensitivity of BCG scar as an index of vaccination status is still the subject of controversy. Failure to form scar may be related to factors such as lack of maturation of the immune system, faulty technique or unipotent vaccine.
Adverse effects of Bcg vaccine: were classified, according to World Health Organization definitions , as injection-site abscess, lymphadenitis, severe local reaction, and disseminated BCG infection.
Tuberculin skin test response:
The reaction is read by measuring the diameter of induration (palpable raised, hardened area) across the forearm (perpendicular to the long axis) in millimeters. If there is no induration, the result should be recorded as "0 mm". Erythema (redness) should not be measured.
- 5 mm or more is positive in
- An HIV-positive person
- Persons with recent contacts with a TB patient
- Persons with nodular or fibrotic changes on chest X-ray consistent with old healed TB
- Patients with organ transplants, and other immunosuppressed patients
- 10 mm or more is positive in
- Recent arrivals (less than five years) from high-prevalence countries
- Injection drug users
- Residents and employees of high-risk congregate settings (e.g., prisons, nursing homes, hospitals, homeless shelters, etc.)
- Mycobacteriology lab personnel
- Persons with clinical conditions that place them at high risk (e.g., diabetes, prolonged corticosteroid therapy, leukemia, end-stage renal disease, chronic malabsorption syndromes, low body weight, etc.)
- Children less than four years of age, or children and adolescents exposed to adults in high-risk categories
- 15 mm or more is positive in
- Persons with no known risk factors for TB. the study aims to• Estimate the frequency of children without BCG scar after bcg vaccination.
- Evaluate factors which may affect scar formation.
- Tuberculin skin test response in children without BCG scars if indicated.
- Frequency of vaccine adverse effects
Exclusion criteria:
- Infants with skin lesion on the left forearm.
- Infant treated with steroids or intravenous immune globulins.
- Infants with immunodeficiency.
- Severe sepsis.
- Infants with congenital anomalies.
All cases included in the study will be subjected to
- Full clinical history including: Birth weight, nutritional status, gender, gestational age, weight at time of vaccination, mother awareness.
- Detailed clinical examination: including site of bcg scar.
- Tuberculin test in negative BCG scar children.
- Revaccination of negative BCG scar children.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- bcg vaccine
| Arm | Type | Receives |
|---|---|---|
| bcg vaccinated | Other | Biological: bcg vaccinechildren under five year vaccinated by bcg vaccine |
Who may qualify
- Ages
- 6 months to 5 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (1 listed)
- Children between 6 and 60 months of age.
Key exclusion criteria (4 listed)
- • Infants with skin lesion on the left forearm.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| bcg vaccinelive attenuated vaccine | Biological | bcg vaccinated |
Primary outcome
number of children without bcg scar after bcg vaccination and factors that may lead to that nummber of children with adverse effects from bcg vaccine using clinical data about children included in the study
Time frame: one year
bcg vaccination reaction and adverse effects and factors affecting scar formation
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Mar 2021.
Related trials for BCG Vaccination Reaction
Active, not recruitingPhase 4
Diabetes Diagnosis, Management, Prevention and Education in Guinea-Bissau
Diabetes Mellitus, BCG Vaccination Reaction
Active, not recruitingObservational study
Long Term Effects of BCG Vaccination on Infectious and Immune Mediated Diseases
BCG Vaccination Reaction, Infections
RecruitingPhase 4
Measles and BCG Vaccines for Mother and Child
Vaccine Preventable Disease, Measles
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
mohamed ghazaly, professor principal investigator
assiut universitypediatric hospital
mustafa embaby, assistprof principal investigator
assiut universitypediatric hospital
Questions about this trial
What is this clinical trial studying?
A study testing bcg vaccine in people with BCG Vaccination Reaction, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 16 Mar 2021. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact shimaa mahran, master (01140574639, shimaamahran88@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
number of children without bcg scar after bcg vaccination and factors that may lead to that nummber of children with adverse effects from bcg vaccine using clinical data about children included in the study (time frame: one year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Mar 2021.